News & Updates

The use of tenecteplase in the extended time window of 4.5–24 hours improves functional outcomes in patients with ischaemic stroke when endovascular thrombectomy (EVT) is not immediately available, findings from the phase III TRACE-III* trial suggest.

A study has recently observed the possible protective effect of leptin against the development of Alzheimer’s disease (AD) by improving insulin sensitivity.

Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.

The incidence of venous thromboembolism (VTE) does not appear to significantly differ among patients treated with second-generation antipsychotics (SGAs) such as risperidone, olanzapine, or aripiprazole, results of a study have shown.

Tau-PET outperforms amyloid-β (Aß) PET and MRI as the best neuroimaging marker for predicting progression to dementia in patients with mild cognitive impairment (MCI), a cohort study has shown.

Among various glucose-lowering medications, metformin and sodium glucose co-transporter-2 inhibitors (SGLT2is) are associated with a reduced risk of dementia, as shown in the results of a meta-analysis.